UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Explore work from home jobs that pay well, providing you the opportunity to earn a great income while enjoying the comfort of home.
19,883 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Greg Abel has stepped into Berkshire Hathaway’s top role with a plan that blends steady operations with a measured ap...
Nebius stock fell today after the company announced debt issuance to fund its infrastructure push and key AI partners...
Kick back with a mug of coffee and a plan to level up your portfolio. These weekend reads translate complex market id...
MemeCore completed its second-stage upgrade, slashing gas fees and enabling smoother on-chain activity. The move spar...
AI stocks soared for years, then faced a rigorous test as valuations and demand shifted. This article breaks down wha...
When planet fitness stock plunged after the latest earnings, investors suddenly faced a tough question: buy the dip o...
A leadership shift at the Fed could unleash a string of policy moves. This guide breaks down what changes coming fede...
A major hedge fund just plowed a substantial stake into a gene-editing company, signaling conviction in Beam Therapeu...
When a large investment firm trims a position, it sends a signal to the market. This article explains what timucuan a...
SSR Mining just sold its Copler Mine stake for $1.5 billion. This move reshapes its balance sheet, shifts portfolio r...
In 2026, investors face a pivotal choice between the world's largest gold producer and a nimble challenger. This arti...